Flurpiridaz data shows promise to expand and enhance cardiac PET

Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET. #ASNC
Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET.

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.

Tricuspid valve therapies moving ahead of mitral therapies seeking market approval

Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).
Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Lifesciences Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).

The complexity of the mitral valve has slowed development of new transcatheter technologies, and it now seems much more likely that transcatheter devices for tricuspid valve will push ahead to gain FDA clearances.